What is Charles River Laboratories International Accounts Receivable?
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Charles River Laboratories International's accounts receivables for the quarter that ended in Dec. 2023 was $578 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Charles River Laboratories International's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 52.05.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Charles River Laboratories International's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-72.03.
Charles River Laboratories International Accounts Receivable Historical Data
The historical data trend for Charles River Laboratories International's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Charles River Laboratories International Accounts Receivable Chart
Charles River Laboratories International Annual Data
Charles River Laboratories International Accounts Receivable Calculation
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
Charles River Laboratories International Accounts Receivable Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Charles River Laboratories International's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Charles River Laboratories International's accounts receivable are only considered to be worth 75% of book value:
Charles River Laboratories International's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Charles River Laboratories International Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Charles River Laboratories International's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles River Laboratories International (Charles River Laboratories International) Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRL has been successfully added to your 